Steven Stellman - Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs

Version 1

      Publication Details (including relevant citation   information):

      Muscat, J. E., Chen, S. Q., Richie, J. P., Jr., Altorki, N. K.,   Citron, M., Olson, S., Neugut, A. I., Stellman, S. D. 97  (7) 1732-6-

      Abstract: BACKGROUND: Nonsteroidal   antiinflammatory drugs (NSAIDs) inhibit the development of lung   tumors in experimental animals. To the authors' knowledge there   are little data regarding whether regular use of NSAIDs reduces   the risk of developing lung carcinoma in humans. METHODS: The   association between lung carcinoma risk and regular use of   NSAIDs, including aspirin, was evaluated in a hospital-based   case-control study of 1038 patients and 1002 controls. RESULTS:   The relative risk estimate of lung carcinoma associated with   using NSAIDs 3 times a week or more for 1 or more years   demonstrated an odds ratio (OR) of 0.68 (95% confidence interval   [95% CI], 0.53-0.89). Results were similar when separated by lung   histologic type. The association varied by smoking status. The OR   was 1.28 (95% CI, 0.73-2.25) in never-smokers and 0.60 (95% CI   0.45-0.80) in ever-smokers. The smoking-specific risk estimates   for aspirin were similar to those for all NSAIDs. CONCLUSIONS:   The results of the current study suggest a possible   chemoprotective benefit with the use of NSAIDs among individuals   who are former or current smokers.

      Address (URL): http://www.ncbi.nlm.nih.gov/pubmed/12655530